Advertisement


Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

2016 ASCO Annual Meeting

Advertisement

Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).

  To see the English language version of this discussion, click here.



Related Videos

Breast Cancer

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).

Neuroendocrine Tumors

Heinz-Josef Lenz, MD, and Jonathan R. Strosberg, MD, on the NETTER-1 Trial for Midgut Neuroendocrine Tumors

Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role in response to treatment with PD-L1 immunotherapy and its impact on progression-free survival and overall survival, as well as the link between intrinsic expression subtypes and treatment outcome with atezolizumab (Abstract 104).

Lymphoma

James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma

James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).

Colorectal Cancer

Michael J. Overman, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Interim Results of the CheckMate 142 Trial

Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).

Advertisement

Advertisement




Advertisement